Literature DB >> 1628369

Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients.

M J Tasso1, A V Boddy, L Price, R A Wyllie, A D Pearson, J R Idle.   

Abstract

The pharmacokinetics and metabolism of cyclophosphamide were studied in nine paediatric patients. Plasma samples were obtained from eight subjects and urine was collected from six children during a 24-h period after drug administration. Cyclophosphamide and its major metabolites phosphoramide mustard (PM), carboxyphosphamide (CX), dechloroethylcyclophosphamide (DCCP) and 4-ketocyclophosphamide (KETO) were determined in plasma and urine using high-performance thin-layer chromatography-photographic densitometry (HPTLC-PD). Cyclophosphamide (CP) was nearly, if not completely, cleared from plasma by 24 h after its administration. The plasma half-life of CP ranged from 2.15 to 8.15 h; it decreased following higher doses and was shorter than that previously reported for adult patients. Both the apparent volume of distribution (0.49 +/- 1.4 l/kg) and the total body clearance (2.14 +/- 1.4 l m-2 h-1) increased with increasing dose. Renal clearance ranged between 0.12 and 0.58 l/h (mean, 0.43 +/- 0.19 l/h). Between 5.4% and 86.1% of the total delivered dose was recovered as unchanged drug in the urine. The major metabolites identified in plasma and urine were PM and CX. One patient appeared to be deficient in CX formation. This study suggests that there is interpatient variability in the pharmacokinetics and metabolism of CP in paediatric patients. The shorter half-life and higher clearance as compared with adult values indicate faster CP metabolism in children.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1628369     DOI: 10.1007/bf00686313

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Combined thin-layer chromatography-photography-densitometry for the quantitation of cyclophosphamide and its four principal urinary metabolites.

Authors:  A H Hadidi; J R Idle
Journal:  J Chromatogr       Date:  1988-05-13

2.  Kinetic characterization of the catalysis of "activated" cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenases.

Authors:  C L Manthey; N E Sladek
Journal:  Biochem Pharmacol       Date:  1988-07-15       Impact factor: 5.858

3.  The biotransformation of cyclophosphamide in man: influence of prednisone.

Authors:  O K Faber; H T Mouridsen; L Skovsted
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-09

4.  Pharmacokinetics of cyclophosphamide in Kenyan African children with lymphoma.

Authors:  F D Juma; D K Koech; E G Kasili; T Ogada
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

5.  Repeated investigations of cyclophosphamide disposition in myeloma patients receiving intermittent chemotherapy.

Authors:  G Edwards; R T Calvert; D Crowther; V Bramwell; H Scarffe
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

6.  Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

Review 7.  Cyclophosphamide: use in practice.

Authors:  M E Gershwin; E J Goetzl; A D Steinberg
Journal:  Ann Intern Med       Date:  1974-04       Impact factor: 25.391

8.  PLasma half-life and urinary excretion of cyclophosphamide in children.

Authors:  N E Sladek; J Priest; D Doeden; C J Mirocha; S Pathre; W Krivit
Journal:  Cancer Treat Rep       Date:  1980 Oct-Nov

9.  Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma.

Authors:  C Erlichman; S J Soldin; R W Hardy; J J Thiessen; J F Sturgeon; S Fine; T Baskerville
Journal:  Arzneimittelforschung       Date:  1988-06

10.  Decreased plasma half-life of cyclophosphamide during repeated high-dose administration.

Authors:  M I Graham; I C Shaw; R L Souhami; B Sidau; P G Harper; A E McLean
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more
  7 in total

1.  Human metabolites and transformation products of cyclophosphamide and ifosfamide: analysis, occurrence and formation during abiotic treatments.

Authors:  Marjeta Česen; Tina Kosjek; Francesco Busetti; Boris Kompare; Ester Heath
Journal:  Environ Sci Pollut Res Int       Date:  2016-02-27       Impact factor: 4.223

2.  The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.

Authors:  A V Boddy; M Cole; A D Pearson; J R Idle
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 3.  Optimizing Rhabdomyosarcoma Treatment in Adolescents and Young Adults.

Authors:  Atsushi Makimoto
Journal:  Cancers (Basel)       Date:  2022-05-02       Impact factor: 6.575

4.  Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group.

Authors:  Jeannine S McCune; David H Salinger; Paolo Vicini; Celeste Oglesby; David K Blough; Julie R Park
Journal:  J Clin Pharmacol       Date:  2008-10-16       Impact factor: 3.126

Review 5.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

Review 6.  Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.

Authors:  Charlotte I S Barker; Eva Germovsek; Rollo L Hoare; Jodi M Lestner; Joanna Lewis; Joseph F Standing
Journal:  Adv Drug Deliv Rev       Date:  2014-01-17       Impact factor: 15.470

7.  Chemotherapy drugs cyclophosphamide, cisplatin and doxorubicin induce germ cell loss in an in vitro model of the prepubertal testis.

Authors:  Ellie Smart; Federica Lopes; Siobhan Rice; Boglarka Nagy; Richard A Anderson; Rod T Mitchell; Norah Spears
Journal:  Sci Rep       Date:  2018-01-29       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.